Guangzhou JEEP Biotechnology: difference between revisions
Diff·revision 32 → 33·07:33, 22 Jan 2025
Difference between revision 32 and revision 33 of Guangzhou JEEP Biotechnology. 1 line changed; the page grew by 102 bytes.
| Revision 32 — 23:15, 12 Jan 2025 ArchiveAudit (talk) expand §Notability and coverage 7,782 bytes ±0 | Revision 33 — 07:33, 22 Jan 2025 NAION_Noel (talk) correct percentage: source reports placebo-adjusted 7,884 bytes +102 | ||
|---|---|---|---|
| 19 | }} | 19 | }} |
| 20 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} | 20 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} |
| + | 21 | {{primarysources|date=July 2026|talk=Concentrated catalogue makes the report set more interpretable}} | |
| 21 | 22 | ||
| 22 | '''Guangzhou JEEP Biotechnology Co., Ltd.''' (trading as '''JEEP'''; jeepbio.com) is a research-peptide manufacturer based in Guangzhou, Guangdong, China, trading as JEEP Peptides, with a catalogue concentrated on incretin analogues and a substantial associated third-party testing record.{{r|registry,selfpub}} | 23 | '''Guangzhou JEEP Biotechnology Co., Ltd.''' (trading as '''JEEP'''; jeepbio.com) is a research-peptide manufacturer based in Guangzhou, Guangdong, China, trading as JEEP Peptides, with a catalogue concentrated on incretin analogues and a substantial associated third-party testing record.{{r|registry,selfpub}} |